key: cord-1005532-jj79xe37
authors: Lippi, Giuseppe; Henry, Brandon Michael
title: Pooled analysis of mid-regional pro-adrenomedullin values in COVID-19 patients with critical illness
date: 2021-05-07
journal: Intern Emerg Med
DOI: 10.1007/s11739-021-02756-2
sha: 9e4629c2a128f64b4c263ec490f772d79852b973
doc_id: 1005532
cord_uid: jj79xe37

nan

proAdrenomedullin" OR "MR-proADM" AND "coronavirus disease 2019" OR "COVID-19" within all fields, and without language or date limits (i.e., up to April 20, 2021). The two authors reviewed title, abstract and full text of all documents identified with these search criteria, selecting studies which described MR-proADM values in COVID-19 patients with different degrees of illness severity. The references list of each of these articles was also scrutinized for identifying other eligible documents. Mean and standard deviation (SD) of MR-proADM values were included in a pooled analysis, with estimation of weighted mean difference (WMD) and 95% confidence interval (95% CI) in COVID-19 patients with or without critical illness. When mean value and SD were unavailable, they were estimated from sample size, median and interquartile range (IQR), as suggested by Hozo et al. [6] . When multiple MR-proADM values were shown, those corresponding to COVID-19 peak severity were selected. A quality effects model was used for pooled analysis, whilst a second random effects model was also calculated to adjust for heterogeneity emerging across different studies. Heterogeneity was evaluated with the χ 2 test and I 2 statistic. The statistical analysis was performed using MetaXL, software Version 5.3 (EpiGear International Pty Ltd., Sunrise Beach, Australia). The study was conducted in agreement with the declaration of Helsinki and within the terms of local legislation.

The electronic search carried out in accordance the above-mentioned criteria identified 34 documents after elimination of duplicates. Among these, 28 were excluded as they were review articles (n = 13), editorial material (n = 1) or correspondence without original data (n = 2), did not specifically deal with COVID-19 (n = 6), did not provide MR-proADM values (n = 2), lack of complete information on MR-proADM values (n = 1), or MR-proADM values were not stratified according to COVID-19 severity (n = 3 [7] [8] [9] [10] [11] [12] . All included studies were cross sectional investigations, three conducted in Italy, while the others were located in Germany, Russia and Switzerland. The clinical endpoints used for characterizing critical illness of COVID-19 were cumulative mortality in two studies, as opposed to intensive care unit (ICU) admission or death, need for renal replacement therapy (RRT), death or intubation, and acute respiratory distress syndrome (ARDS) in the remaining investigations ( Table 1 ). The pooled analysis of these six studies is shown in Fig. 1 , demonstrating a positive difference of MR-proADM values between patients with or without critical COVID-19 in each individual study. The WMD of MR-proADM values in COVID-19 patients with critical illness versus those without was 0.67 (95% CI 0.42-0.93) nmol/L in the quality effects model (with high heterogeneity, I 2 = 81%) (Fig. 1) , further increasing to 0.80 (95% CI 0.58-1.02) nmol/L in the random effects model. Overall, MR-proADM values were found to be increased by 74% (95% CI 46-103%) in COVID-19 patients with critical illness compared to those without.

Notably, two studies among those excluded deserve special mention. Hupf et al. assayed ADM gene expression rather than the circulating hormone concentration in 21 COVID-19 patients and, in agreement with our findings on MR-proADM levels, they reported significantly higher values in subjects who died than in those who survived [13] . In a subsequent investigation, which could not be included in the pooled analysis due to lack of complete information on MR-proADM values, Benedetti et al. found that the median concentration of this biomarker was significantly higher in COVID-19 patients who died (11/21; 52%) that in those who survived (3.5 vs. 0.8 nmol/L; p = 0.006) [14] . As concerns the possible mechanisms underpinning the negative effect of MR-proADM on infectious diseases course, including COVID-19, this molecule is deeply involved in the inflammatory response and in progression from sepsis to septic shock [1] . In both conditions, vascular endothelium represent the most predominant source of MR-proADM, although other organs may contribute to its production. Since endothelial injury is commonplace in patients with COVID-19, and progression to critical illness is always associated with multiple organ failure [15] , MR-proADM assessments may hence represent a valuable tool for monitoring disease severity and stratifying the risk of critical illness or death. [12] Italy 69 (58% severe) ARDS 2.30 ± 1.11 vs. 1.12 ± 0.45 Fig. 1 Weighted mean difference (WMD) and 95% confidence interval (95% CI) of mid-regional pro-adrenomedullin (MR-proADM) in patients with coronavirus disease 2019 (COVID-19) with or without critical illness

Funding No financial support was provided relevant to this article.

Conflict of interest All authors report no conflicts of interest relevant to this article.

Ethical approval Not applicable.

Human and animal rights Not applicable.

Informed consent Not applicable.

Midregional pro-adrenomedullin (MR-proADM) as a biomarker for sepsis and septic shock: narrative review

New role of biomarkers: mid-regional proadrenomedullin, the biomarker of organ failure

Prognostic value of midregional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and metaanalysis

Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology

Risks and features of secondary infections in severe and critical ill COVID-19 patients

Estimating the mean and variance from the median, range, and the size of a sample

The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study

Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: an observational prospective study

Predictive value of proadrenomedullin in patients with COVID-19

MR-proAdrenomedullin as predictor of renal replacement therapy in a cohort of critically ill patients with COVID-19

MR-proADM as prognostic factor of outcome in COVID-19 patients

High value of midregional proAdrenomedullin in COVID-19: a marker of widespread endothelial damage, disease severity and mortality

RNA-expression of adrenomedullin is increased in patients with severe COVID-19

High levels of mid-regional proadrenomedullin in ARDS COVID-19 patients: the experience of a single, Italian center

COVID-19: unravelling the clinical progression of nature's virtually perfect biological weapon